INTRODUCTION {#s1}
============

Hip fracture as a serious consequence of osteoporosis is becoming an important health problem, and an increasing social and economic burden \[[@R1]--[@R3]\], and hip fractures are expected to receive more attention over the coming years \[[@R4]--[@R6]\]. Cenzer et al \[[@R7]\] reported that about 27% hip fracture patients dead during the 1-year follow up. Multiple factors have been shown to be associated with the risk of hip fractures \[[@R8]--[@R11]\]. It is widely recognized that vitamin D plays an important role in skeletal health \[[@R12]--[@R15]\].

Serum 25-hydroxyvitamin D \[25(OH)D\] is widely recognized as the indicator of vitamin D \[[@R16]\]. Steingrimsdottir et al \[[@R17]\] found that serum 25(OH)D \< 30 nmol had higher risk of hip fractures than the 25(OH)D with 50-75 nmol/L (Hazard ratios: 2.24 (95% CI 1.63, 3.09)). Similar result was found in study of Looker et al \[[@R18]\]. However, in study of Barbour et al \[[@R19]\], they found no evidence of an association between 25(OH)D and any non-spine fractures, and similar result was found in studies of Cummings et al \[[@R20]\] (25(OH)D less than 47.5 nmol/L (19 ng/ml) with RR: 1.2 (0.7-1.9)), Chan et al \[[@R21]\] with (RR: 0.63 (0.15-2.62)), and de Boer et al \[[@R22]\] with (RR: 1.34 (0.97-1.84)).

Therefore, the effect of serum 25(OH)D concentrations on hip fracture remains uncertain, and we conducted this meta-analysis for the purpose of determining the association between serum 25(OH)D concentrations and the risk of hip fracture. Moreover, which is optimal serum 25(OH)D concentration? And will the sex, age, geographic region or study design (cohort or nested case-cohort) influence the outcomes? Dose-response and subgroup analysis (sex, age, geographic region or study design) were performed to help us understand more about serum 25(OH)D levels and their relationship to the risk of hip fracture.

RESULTS {#s2}
=======

Literature search {#s2_1}
-----------------

The detailed steps of our literature selection are shown in Figure [1](#F1){ref-type="fig"}. A total of 399 potential records were identified from the databases, including 88 duplicate articles, 311 articles leaved after duplications deleted; then, 222 papers were excluded by screening the abstracts, and 89 full articles were retrieved. There were 74 articles excluded, including 11 review articles, 12 studies that examined other types of fractures and 25(OH)D, 17 non-prospective cohort studies, 2 meeting articles, 17 articles about other factors affecting the bone health (not including fracture) and 25(OH)D, and 15 studies research the prevalence of vitamin D insufficiency in patient of any kind of fracture (didn\'t have hip fracture data). Overall, Fifteen prospective cohort studies \[[@R17]--[@R31]\] that referred to the relationship between serum 25(OH)D levels and hip fractures were included.

![The selection of literature for included studies](oncotarget-08-39849-g001){#F1}

Study characteristics {#s2_2}
---------------------

The characteristics of the included studies are presented in Table [1](#T1){ref-type="table"}. A total of 51239 participants were included in our meta-analysis, of whom 3386 had a hip fracture. Fourteen of the fifteen studies were conducted during the period from 2007 to 2016, and there was only one article that was conducted in 1998. Of these fifteen studies, there were eleven cohort studies and four nested case-cohort studies; five of the studies were conducted in Europe and eight were conducted in the United States, one was conducted in the HongKong and one was conducted in the New Zealand. These studies met the criteria for high quality (7 to 9 stars). Most studies provided risk estimates that were adjusted for age (14 studies), BMI (10 studies), gender (8 studies), drinking (7 studies), smoking (10 studies), physical activity (7 studies) and weight (4 studies) (Table [1](#T1){ref-type="table"}).

###### Characteristics of Prospective Studies on Serum 25-Hydroxyvitamin D and Hip Fracture

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source                    Study Type          No. of participants   Location/\        Gender    Age\      No. of casesa   Measure/Range of concentrations   Study\     Adjustment for Covariatesc
                                                                      Period                      (years)                                                     Qualityb   
  ------------------------- ------------------- --------------------- ----------------- --------- --------- --------------- --------------------------------- ---------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Steingrimsdottir et al\   Cohort study        5461                  Iceland\          F:3125\   66--96    261HF           Q1\<30 nmol/L\                    9          Age, sex, body mass index, height, smoking, alcohol intake and season,physical activity.
  2014                                                                2002-2009         M:2346                              30 nmol/L≤Q2\<50 nmol/L\                     
                                                                                                                            50 nmol/L≤Q3\<75 nmol/L\                     
                                                                                                                            Q4≥75 nmol/L\                                
                                                                                                                            (Immune based)                               

  Khaw et al\               Cohort study        14641                 United Kingdom\   F:8155\   42--82    198HF           Q1\<30 nmol/L\                    9          Age, sex, month, BMI, physical activity, smoking, alcohol, vitamin C, diabetes, history of cardiovascular disease, history of cancer, social class, and education .
  2014                                                                1997-2012         M:6486                              30 nmol/L≤Q2\<50 nmol/L\                     
                                                                                                                            50 nmol/L≤Q3\<70 nmol/L\                     
                                                                                                                            70 nmol/L≤Q4 \<90 nmol/L\                    
                                                                                                                            Q5≥90 nmol/L\                                
                                                                                                                            (Chromatography based)                       

  Barbour et al\            Cohort study        2640                  United States\    F:1291\   70-79     84 HF           Q1≤44.45 nmol/L\                  9          Age, gender, race, education level, season of blood draw, BMI, current drinking, fracture after age 45 and clinical comorbidity index.
  2012                                                                1997-2009         M:1349                              44.48 nmol/L≤Q2≤60.9 nmol/L\                 
                                                                                                                            60.93 nmol/L≤Q3≤79.85 nmol/L\                
                                                                                                                            Q4\> 79.85nmol/L\                            
                                                                                                                            (Immune based)                               

  Robinson-Cohen et al\     Cohort study        2294                  United States\    F:1600\   ≥65       244HF           Q1\<37.5nmol/L\                   8          Age, race, sex, clinic site, a season, education, smoking status (never smoker, former smoker, or current, smoker), alcohol use (any vs. none), diabetes status (normal, impaired fasting glucose, or diabetes), body mass index, self-reported health status, physical activity level, oral steroid use, estrogen use, thiamine and loop diuretic use, serum cystatin C level, and calcium supplement use.
  2011                                                                1989--2009        M:694                               Q2≥37.5nmol/L\                               
                                                                                                                            (Chromatography based)                       

  Looker et al\             Cohort study        1917                  United States\    F:986\    ≥65       156HF           0nmol/L≤Q1≤42.9 nmol/L\           9          Age, sex, femoral neck BMD, BMI, previous fracture, dietary calcium, kilocalories, and weight loss from maximum.
  2008                                                                1991--2000        M:931                               43nmol/L≤Q2≤61 nmol/L\                       
                                                                                                                            61.1nmol/L≤Q3\<82.5 nmol/L\                  
                                                                                                                            Q4 ≥82.5nmol/L\                              
                                                                                                                            (Immune based)                               

  Holvik et al\             Case-cohort study   2526                  Norway\           F:1819\   65-79     1175HF          4.5 nmol/L≤Q1≤42.1 nmol/L\        9          Age, gender, study center, BMI, and month of blood sample.
  2013                                                                1994--2001        M:707                               42.2 nmol/L≤Q2\<53.5 nmol/L\                 
                                                                                                                            53.5 nmol/L≤Q3≤67.8nmol/L\                   
                                                                                                                            67.9 nmol/L≤Q4≤250.0 nmol/L\                 
                                                                                                                            (Mass spectrometry)                          

  Cauley et al\             Case-cohort study   1665                  United States\    M:1665    ≥65       81HF            7.83 nmol/L≤Q1\<47.5 nmol/L\      8          Age, race, clinic, season of blood draw, physical activity, weight, and height.
  2010                                                                2000-2002                                             47.5 nmol/L≤Q2\<62.75 nmol/L\                
                                                                                                                            62.75 nmol/L≤Q3\<74.75 nmol/L\               
                                                                                                                            Q4≥74.75 nmol/L\                             
                                                                                                                            (Chromatography based)                       

  Cauley et al\             Case-cohort study   800                   United States\    F:800     50-79     400HF           9.23 nmol/L≤Q1\<47.6 nmol/L\      9          Age, body mass index, parental history of hip fracture, history of fracture, smoking, alcohol use, and total calcium intake, oral corticosteroid use and geographic region.
  2008                                                                1994-2004                                             47.6nmol/L≤Q2\<60.2 nmol/L\                  
                                                                                                                            60.2 nmol/L≤Q3\<70.7nmol/L\                  
                                                                                                                            70.7 nmol/L≤Q4\<121.5 nmol/L\                
                                                                                                                            (Immune based)                               

  Cummings et al\           Case-cohort study   476                   United States\    F:476     ≥65       133HF           Q1\<47.5 nmol/L\                  8          Age and weight
  1998                                                                1986-1988                                             Q2≥47.5 nmol/L\                              
                                                                                                                            (Immune based)                               

  Bolland et al 2010        Cohort study        1471                  New Zealand\      F:1471    \>50      22HF            Q1\<50 nmol/L\                    9          Treatment allocation (calcium or placebo) and baseline age, body weight, and smoking status.
                                                                      1998-2003                                             Q2≥50 nmol/L\                                
                                                                                                                            (Immune based)                               

  Melhus et al 2010         Cohort study        1194                  Sweden            M:1194    \>50      73HF            Q1\<50 nmol/L\                    9          Weight, height, age, cystatin C, calcium intake, season, physical activity, smoking, diabetes mellitus, other endocrine disease, hematological diseases, dermatoses, infectious disease, musculoskeletal disease, psychiatric disease, neurological disease, respiratory disease, kidney or urinary disease, gastrointestinal disease.
                                                                                                                            Q2≥50 nmol/L\                                
                                                                                                                            (Chromatography based)                       

  Chan et al 2011           Cohort study        712                   HongKong          M:712     ≥65       24HF            Q1≤63 nmol/L\                     9          Age, BMI, education, PASE, DQI, smoking status, and alcohol use
                                                                                                                            63 nmol/L\<Q2≤76 nmol/L\                     
                                                                                                                            76 nmol/L\<Q3≤91 nmol/L\                     
                                                                                                                            Q4\>91 nmol/L\                               
                                                                                                                            (Immune based)                               

  Buchebner et al 2014      Cohort study        1044                  Sweden            F:1044    ≥75       130HF           Q1\<50 nmol/L\                    7          smoking, bisphosphonate use, and physical activity level
                                                                                                                            50 nmol/L≤Q2≤75 nmol/L\                      
                                                                                                                            Q3\>75 nmol/L\                               
                                                                                                                            (Chromatography based)                       

  de Boer et al 2012        Cohort study        1621                  United States\    F:1130\   ≥65       137HF           Q1\<50 nmol/L\                    9          Age, sex, clinical site, smoking, body mass index, and physical activity.
                                                                      1992--2006        M:491                               Q2≥50 nmol/L                                 

  Takiar et al 2015         Cohort study        12781                 United States\    F:7196\   Mean 57   267HF           Q1\<50 nmol/L\                    9          Age, sex, and race/cente, potentially confounding variables of education, annual household income, physical activity, smoking status, alcohol drinking status, body mass index, waist-to-hip ratio, diabetes, systolic and diastolic blood pressure, use of hypertension medication, total and HDL cholesterol, estimated glomerular filtration rate, thiazide diuretic usage, and hormone replacement therapy, calcium, phosphate, and PTH levels.
                                                                      1990-1992         M:5585                              Q2≥50 nmol/L                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

a: HF: Hip fracture.

b: Study quality was judged based on the Newcastle-Ottawa Scale (range, 1-9 stars).

c: BMI: body mass index; BMD: Bone mineral density.

Serum 25(OH)D levels and hip fracture risk {#s2_3}
------------------------------------------

There were thirteen studies that referred to the relationship between serum 25(OH)D levels and the risk of hip fracture. The results of the meta-analysis are shown in Figure [2](#F2){ref-type="fig"}. The pooled adjusted RRs of hip fracture for the lowest *versus* highest categories of serum 25(OH)D concentrations were 1.58 (1.41, 1.77) without significant heterogeneity (I^2^ = 16.8%, *P* = 0.265), the meta-regression of year, age, follow-up term, study-type, gender and location showed no heterogeneity was found (all of the *P* \> 0.10, [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Additionally, there was no indication of significant publication bias *via* Egger\'s test (*P* = 0.427).

![Dose-response relationship between serum 25(OH)D and relative risk of hip fracture\
Solid line represents adjusted relative risk and dotted lines represent the 95% confidence intervals for the fitted trend. Adj.RR of hip fracture is a descending curve below the line of RR = 1. The descending trend was obvious when serum 25(OH)D level was less than 60 nmol/L, and flat when serum 25(OH)D was higher than 60 nmol/L; there was no significant linear association between the serum 25(OH)D levels and the risk of hip fracture (*P* = 0.110 for non-linearity).](oncotarget-08-39849-g002){#F2}

Subgroup meta-analysis {#s2_4}
----------------------

The results of the subgroup meta-analysis are shown in the Table [2](#T2){ref-type="table"}. We found that low levels of serum 25(OH)D increased the risk of hip fracture when it was defined by gender (male: 1.86 (1.36 to 2.56); female: 1.45 (1.20 to 1.70)), age (≥ 65 years: 1.61 (1.41 to 1.84); ≥ 42 years: 1.49 (1.19 to 1.85)), location (Europe: 1.64 (1.37 to 1.97); USA: 1.56 (1.34 to 1.80)), study type (cohort: 1.67 (1.45 to 1.93); nested case-cohort: 1.42 (1.17 to 1.72)), and duration of follow-up (\< 7 years: 1.89 (1.52 to 2.35); ≥ 7 years: 1.48 (1.29 to 1.69)).

###### Subgroup analyses for 25(OH)D and hip fracture

                          No. of reports   Relative Risk (95CI%)   *P* for heterogeneity   *I*^2^   *P* for test
  ----------------------- ---------------- ----------------------- ----------------------- -------- --------------
  Sex                                                                                               
  Male                    5                1.86 (1.36 to 2.56)     0.695                   0.0      0.000
  Female                  6                1.45 (1.20 to 1.75)     0.181                   34.1     0.000
  Age                                                                                               
  ≥65 years               10               1.61 (1.41 to 1.84)     0.110                   37.3     0.000
  ≥42years                5                1.49 (1.19 to 1.85)     0.722                   0        0.000
  Location                                                                                          
  Europe                  5                1.64 (1.37 to 1.97)     0.096                   49.2     0.000
  USA                     8                1.56 (1.34 to 1.80)     0.355                   9.7      0.000
  Study type                                                                                        
  Cohort                  11               1.67 (1.45 to 1.93)     0.277                   17.5     0.000
  Case-cohort             4                1.42 (1.17 to 1.72)     0.418                   0.0      0.000
  Duration of follow-up                                                                             
  \<7 years               7                1.89 (1.52 to 2.35)     0.271                   20.8     0.000
  ≥7 years                6                1.48 (1.29 to 1.69)     0.575                   0.0      0.000

Dose-response meta-analysis {#s2_5}
---------------------------

Four studies \[[@R17], [@R21], [@R24], [@R26]\] of serum 25(OH)D concentration and risk of hip fracture met the dose-response meta-analysis criteria. The results of generalized least-squares regression for serum 25(OH)D levels and the adj.RR of hip fracture are shown in the Figure [3](#F3){ref-type="fig"} as a descending curve below the line of RR = 1. The descending trend was obvious when the serum 25(OH)D level was below 60 nmol/L and flattened when the serum 25(OH)D level was higher than 60 nmol/L; there was no significant linear association between the serum 25(OH)D levels and the risk of hip fracture (*P* = 0.110 for non-linearity, Figure [3](#F3){ref-type="fig"}).

![Adjusted Relative Risks of hip fracture for the lowest\
*vs*. **highest categories of serum 25(OH)D levels**.](oncotarget-08-39849-g003){#F3}

DISCUSSION {#s3}
==========

Hip fracture has been worldwide burden \[[@R32]\] and the association of low levels of serum 25(OH)D and risk of fracture among older adults was unclear \[[@R18], [@R19], [@R23], [@R25], [@R27], [@R33]\]. A previous meta-analysis based on randomized controlled trials and observational studies \[[@R34]\] showed that neither higher nor lower doses of vitamin D supplementation led to an increased risk of hip fracture; it found that the serum 25(OH)D levels in the 17 identified case-control studies were 33% lower in the case groups compared to the control groups \[[@R34]\].

We found that the adjusted relative risk (adj.RR) of low levels of 25(OH)D has a statistically significant 58% increased risk of hip fracture. All of the subgroup meta-analyses of different genders, age ranges, locations, study types, and durations of follow up supported the result that lower serum 25(OH)D levels significantly increased the risk of hip fracture.

Serum 25(OH)D is the indicator of vitamin D. Therefore, low levels of serum 25(OH)D may be associated with bone loss, lower bone mineral density (BMD) and higher bone turnover \[[@R35]\], which may cause a high risk of fracture. Some other indirect factors may increase the risk of hip fracture, including muscle strength, balance and intake of nutrients; the deficiency of vitamin D may decrease muscle strength and balance, and may also be combined with deficiencies of other nutrient \[[@R36]--[@R38]\]. It was also reported that vitamin D deficiency may increase the risk of falls, which then may increase hip fracture risk \[[@R39], [@R40]\]. Finally, low levels of serum 25(OH)D may be connected with poor health status, which also causes an increase in the risk of hip fracture \[[@R41]\].

The guidelines published by the Institute of Medicine (IOM) recommend that serum 25(OH)D levels ≥ 50 nmol/L(≥ 20 ng/ml) can benefit skeletal health \[[@R12]\]. In this study, the dose-response meta-analysis showed a descending curve below the line of RR = 1, which was consistent with the results of the forest plot in Figure [2](#F2){ref-type="fig"}; however, no significant curvilinear association between serum 25(OH)D levels and the risk of hip fracture was found. Additionally, using the RR curve in Figure [3](#F3){ref-type="fig"}, we found that the curve descended before the level of 60 nmol/L, then the curve trend became flat; therefore, when serum 25(OH)D levels are \< 60 nmol/L, increasing serum 25(OH)D levels may significantly decrease the risk of hip fracture, and after reaching 60 nmol/L, increasing serum 25(OH)D levels will not decrease the risk of hip fracture. The transitional serum 25(OH)D level in this meta-analysis (60 nmol/L) was 10 nmol/L higher than that recommended by the Institute of Medicine (IOM) (≥ 50 nmol/L) \[[@R12]\].

Strengths of this study {#s3_1}
-----------------------

The strength of this meta-analysis is that our quantitative assessment is based on prospective cohort studies, which can overcome the weaknesses of recall and selection bias in case-control studies and provide more data on hip fracture risk within the population. To the best of our knowledge, this is the first systematic review and meta-analysis of the relationship between serum 25(OH)D levels and the risk of hip fracture based on prospective cohort studies. Moreover, we performed subgroup analyses by gender, age, location, study design and follow-up term, and the results were consistent to the overall result. We also performed dose-response assessments of the relationship between serum 25(OH)D levels and the risk of hip fracture. Finally, all of the included studies had high quality assessment scores (7-9 stars, nine-star Newcastle-Ottawa scale) and long durations of follow-up, with a large population of 51239 participants totally.

Limitations of this study {#s3_2}
-------------------------

There are still some limitations of our meta-analysis. Firstly, not all of the studies met the requirement of dose-response meta-analysis; only four of included studies were pooled for dose-response meta-analysis. Secondly, There were some different 25(OH)D assays exist, in general, they can be grouped into 2 different categories: immune based and chromatography based \[[@R42]\]. According to the current views, the intra-assay variation may reach 0-10%, while the inter-assay variation may reach 0-25% (at lower serum levels) \[[@R43], [@R44]\]. Therefore, the variation is existed, and can\'t be avoided, we should be kept in mind when following an individual patient over time \[[@R44]\]. Thirdly, some factors that vitamin D measurements in blood samples drawn from fracture patients in the acute phase may be influenced by the trauma and surgery itself-such as by inflammation \[[@R45]\] or hemodilution caused by fluid supply \[[@R46]\].

CONCLUSIONS AND CLINICAL IMPLICATION {#s4}
====================================

Individuals with low levels of serum 25(OH)D have an increased risk of hip fracture, and this effect was evident when the serum 25(OH)D level was less than 60 nmol/L, and disappeared when the serum 25(OH)D level was more than 60 nmol/L.

MATERIALS AND METHODS {#s5}
=====================

The present study was completed according to the preferred reporting items for systematic review and meta-analyses (PRISMA) statement (Checklist S1).

Search strategy {#s5_1}
---------------

We systematically searched PubMed and EMBASE on September 15, 2016 using the following keywords: 1) 25-hydroxyvitamin D, 25(OH)D, or vitamin D; 2) hip fractures or hip fracture; 3) cohort study, cohort studies, prospective study, prospective studies, or longitudinal study. We conducted the searches without language and publication year restrictions. In addition, we manually scanned the related articles and used the "related article" function for additional searches to avoid initial misses.

Selection criteria {#s5_2}
------------------

The criteria for inclusion in this meta-analysis were as follows: (1) the study was designed as a prospective cohort study; (2) exposure of interest is 25(OH)D; (3) primary outcome of interest is hip fracture; and (4) relative risk (RR) and the corresponding 95% confidence interval (CI) were reported or could be calculated using the data reported. If the data were overlapped or duplicated by multiple publications, the study with the larger number of cases was included

And the criteria of exclusion were: (1) the retrospective study; (2) No data of 25(OH)D and hip fracture was described; (2) meeting abstract that couldn\'t found the full text; (4) the RR and 95%CI were not reported or couldn\'t be calculated using the reported data.

Two authors (QBL and XG) independently scanned the potential studies to determine which studies were eligible. Disagreements were discussed first and resolved by a third independent author (AMW).

Data extraction {#s5_3}
---------------

Three investigators (XL, QHX and ZXS) independently extracted data and the other author (YLC) cross-checked the data for consistency. Differences and disagreements were resolved by consensus. The data were recorded using a standard data extraction form, including the first author\'s last name, publication year, country where the study was performed, study period, sample size (cases and controls or cohort size), gender and age of participants, measure and range of exposure, variables adjusted for analysis, and RR estimates with corresponding 95% CI for each category of 25(OH)D. If there were more RRs for different potential confounders, we extracted the RRs that reflected the greatest degree of control for potential confounders. If necessary, we contacted the authors of the primary studies for additional information. The nine-star Newcastle-Ottawa scale was used to assess the study quality \[[@R47], [@R48]\].

Statistical analysis {#s5_4}
--------------------

First, RR estimates were combined using a fixed-effects model as a common measure of the relationship between serum 25(OD)D levels and the risk of hip fracture across studies. To obtain a more accurate result, we pooled the RRs and 95%CIs of the lowest *vs*. the highest categories for synthesis to determine the risk of hip fracture with low 25(OH)D concentrations \[[@R49]--[@R51]\].

Second, we conducted a subgroup meta-analysis to examine the significance of the difference in RRs by different subgroups, including gender (male and female), age (≥ 65 years and ≥ 42 years), location (Europe and USA), study type (cohort study and case cohort study) and the duration of follow-up (\< 7 years and ≥ 7 years). And the covariates (year, age, follow-up term, study-type, gender and location) meta-regression was performed to observe the potential heterogeneity.

Third, to examine the association between 25(OH)D levels and the risk of hip fractures, a dose-response meta-analysis was fitted using 4 knots at the following percentiles of distribution: 5%, 35%, 65% and 95% of the distribution \[[@R52]\]. We used the random-effects model reported by Greenland and Longnecker \[[@R53]\] and Orsini et al \[[@R54]\] to conduct a dose-response meta-analysis of 25(OH)D levels. For consistency within the included studies, 25(OH)D concentrations are reported in "nmol/L". Concentrations reported in "ng/ml" by some studies were converted using a conversion factor (1 ng/ml = 2.5 nmol/L).

Finally, statistical heterogeneity between studies was quantified by using Cochran\'s Q and the I^2^ statistic \[[@R55]\]. To investigate the influence of the individual data on the pooled results, we performed a sensitivity analysis to assess the influence of a single study on the pooled RR estimate by removing one study at a time. We also performed the Egger\'s asymmetry regression test to evaluate potential publication bias \[[@R56]\]. All statistical tests were performed using STATA software (Version 12.0; Stata Corp, College Station, Texas).
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